Trial reportJournal of Alzheimer's disease : JAD2018
Effects of Composite Supplement Containing Astaxanthin and Sesamin on Cognitive Functions in People with Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial.
Trial report in Journal of Alzheimer's disease : JAD, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Natural Products in Alzheimer's Disease: A Systematic Review of Clinical Trials and Underlying Molecular Mechanisms.International journal of molecular sciences · 2025Pooled it
- Pooled it
- Pooled it
- Efficacy and Safety ofNutrients · 2025Trial
- Efficacy and Safety ofNutrients · 2019Trial
- The Protective Role of Astaxanthin for UV-Induced Skin Deterioration in Healthy People-A Randomized, Double-Blind, Placebo-Controlled Trial.Nutrients · 2018Trial
- Gut microbiota and aging: current understanding and future perspectives.Molecular biomedicine · 2026Review
- Marine Lipids and Alzheimer's Disease: Biochemistry, Bioaccessibility/Bioavailability, Metabolism, and Health Effects.Marine drugs · 2026Review
- Astaxanthin Delivery Across Administration Routes: Recent Advances to Improve Stability and Bioavailability.Pharmaceutics · 2026Review
- Polyphenols and Neurodegenerative Diseases: Knowledge-Mining Insights, Mechanistic Evidence, and Emerging Nutritional Applications.Nutrients · 2026Review
- Probiotic Supplementation Improves the Clinical Measures of Cognition in Patients With Mild Cognitive Impairment.Cureus · 2025Review
- Promising benefits of six-monthFrontiers in aging · 2025Article
- Astaxanthin as a neuroprotective modulator of synaptic plasticity, learning, and memory: mechanistic insights and therapeutic perspectives in neurodegenerative aging.Frontiers in aging neuroscience · 2025Review
- The Effects of Astaxanthin on Cognitive Function and Neurodegeneration in Humans: A Critical Review.Nutrients · 2024Review
- Negative Association of Lignan and Phytosterol Intake with Stress Perception during the COVID-19 Pandemic-A Polish Study on Young Adults.Nutrients · 2024Article
- Recent advancements in the role of phytochemicals and medicinal plants in prophylaxis and management of Alzheimer's disease.Iranian journal of basic medical sciences · 2024Review
- Krill oil: nutraceutical potential in skin health and disease.Frontiers in nutrition · 2024Review
- Astaxanthin and improvement of dementia: A systematic review of current clinical trials.Cerebral circulation - cognition and behavior · 2024Review
- Astaxanthin: Past, Present, and Future.Marine drugs · 2023Review
- Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDementia and its first or transitional stage, mild cognitive impairment (MCI), is a major concern for the aging Japanese society. Thus, the use of dietary supplements to improve or maintain cognitive function has become a topic of public interest.
objectiveIn this study, we evaluated the effects of a composite supplement containing food-derived antioxidants, specifically astaxanthin and sesamin (AS), on cognitive function in people with MCI.
methodTwenty-one healthy participants with MCI were recruited in our double-blind placebo-controlled pilot study. They were assigned to either an AS group, who received ingestible capsules containing AS, or a placebo group, who received identical placebo capsules. To assess cognitive functions, we performed the Japanese version of the Central Nervous System Vital Signs (CNSVS) test and the Alzheimer's Disease Assessment Scale-Cog test at baseline, after 6 weeks, and after 12 weeks of dietary supplementation.
resultsThe CNSVS test revealed significant improvements in psychomotor speed and processing speed in the AS group compared with the placebo group, suggesting that the daily supplementation of AS improved cognitive functions related to the ability to comprehend, and perform complex tasks quickly and accurately.
conclusionOur results provide support for the use of AS as a dietary supplementation for improving cognitive functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.